CelLBxHealth (FRA:DWV) EPS (Basic): €-0.06 (TTM As of Dec. 2025)


What is CelLBxHealth EPS (Basic)?

CelLBxHealth FRA:DWV +19.35% EPS (Basic) is €-0.06 as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.06.

CelLBxHealth's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.06.

CelLBxHealth's EPS without NRI for the six months ended in Dec. 2025 was €-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.06.

During the past 3 years, the average EPS without NRI Growth Rate was 13.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, CelLBxHealth's highest 3-Year average EPS without NRI Growth Rate was 16.10% per year. The lowest was -75.90% per year. And the median was 0.00% per year.

CelLBxHealth  (FRA:DWV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CelLBxHealth EPS (Basic) Related Terms

CelLBxHealth EPS (Basic) Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth EPS (Basic) Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.10 -0.09 -0.06 -0.06

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.03 -0.02 -0.03 -0.03

CelLBxHealth EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CelLBxHealth's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.303-0)/353.835
=-0.06

CelLBxHealth's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.708-0)/385.141
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.06 mean?
CelLBxHealth (FRA:DWV) has a EPS (Basic) of €-0.06 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's EPS (Basic) too high?
CelLBxHealth's current EPS (Basic) is €-0.06.
How does CelLBxHealth's EPS (Basic) compare to TMO and DHR?
CelLBxHealth's EPS (Basic) of €-0.06 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current EPS (Basic) is €-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 73.6% below its estimated fair value. The current EPS (Basic) is €-0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current EPS (Basic) is €-0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.